» Articles » PMID: 31756206

Expression Profile of Sonic Hedgehog Signaling-related Molecules in Basal Cell Carcinoma

Overview
Journal PLoS One
Date 2019 Nov 23
PMID 31756206
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Basal cell carcinoma (BCC) is the most common human cancer, characterized by aberrant activation of the hedgehog (HH) signaling pathway resulting from mutations in the patched 1 (PTCH1) or smoothened (SMO) genes. In the present study, to uncover the expression profile of HH signaling-related molecules, we thoroughly examined the mRNA and protein expression levels of six molecules including GLI1, GLI2, PTCH1, PTCH2, SHH, and SMO in BCC and various other cutaneous tumors. Real-time PCR analysis demonstrated that BCC showed remarkably enhanced mRNA expression of all HH molecules, except SMO compared to other skin tumors. However, immunohistochemical analysis revealed that only GLI1 protein was specifically upregulated in BCC, while the other HH-related proteins did not show any significant differences between the tumors. Notably, other skin malignancies such as squamous cell carcinoma, sebaceous carcinoma, and malignant melanoma showed no GLI1 expression and there was no difference in GLI1 expression between the BCC subtypes. In addition, GLI1 and GLI2 expression were strongly associated with the hair follicle stem cell markers, LGR4 and LGR5, which are known target genes of the Wnt pathway. Our results suggest that GLI1 has the potential to be a diagnostically useful marker for differentiating BCC from other skin malignancies and an interaction between the HH and Wnt signaling pathways may be involved in the development of BCCs.

Citing Articles

PTCH1 gene variants rs357564, rs2236405, rs2297086 and rs41313327, mRNA and tissue expression in basal cell carcinoma patients from Western Mexico.

Zambrano-Roman M, Padilla-Gutierrez J, Valle Y, Munoz-Valle J, Guevara-Gutierrez E, Martinez-Fernandez D J Clin Lab Anal. 2024; 38(3):e25010.

PMID: 38287479 PMC: 10873687. DOI: 10.1002/jcla.25010.


Clinical and Molecular Features of Morpheaform Basal Cell Carcinoma: A Systematic Review.

Conte S, Ghezelbash S, Nallanathan B, Lefrancois P Curr Oncol. 2023; 30(11):9906-9928.

PMID: 37999140 PMC: 10670319. DOI: 10.3390/curroncol30110720.


Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies.

Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y Signal Transduct Target Ther. 2023; 8(1):315.

PMID: 37596267 PMC: 10439210. DOI: 10.1038/s41392-023-01559-5.


Immunohistochemical Analysis of Single-Stranded DNA Binding Protein 2 in Non-Melanoma Skin Cancers.

Bang S, Son H, Cha H, Song K, Park H, Kim H Biomedicines. 2023; 11(7).

PMID: 37509458 PMC: 10376428. DOI: 10.3390/biomedicines11071818.


Cargo-Dependent Targeted Cellular Uptake Using Quaternized Starch as a Carrier.

Blitsman Y, Benafsha C, Yarza N, Zorea J, Goldbart R, Traitel T Nanomaterials (Basel). 2023; 13(13).

PMID: 37446506 PMC: 10343776. DOI: 10.3390/nano13131988.


References
1.
Bonifas J, Pennypacker S, Chuang P, McMahon A, Williams M, Rosenthal A . Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol. 2001; 116(5):739-42. DOI: 10.1046/j.1523-1747.2001.01315.x. View

2.
Jang B, Lee C, Kim H, Shin M, Cheon M, Kim J . Distinct expression profile of stem cell markers, LGR5 and LGR6, in basaloid skin tumors. Virchows Arch. 2017; 470(3):301-310. DOI: 10.1007/s00428-016-2061-3. View

3.
Wang G, Wang J, Mancianti M, Epstein Jr E . Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell. 2011; 19(1):114-24. PMC: 3061401. DOI: 10.1016/j.ccr.2010.11.007. View

4.
Hahn H, Wicking C, Zaphiropoulous P, Gailani M, Shanley S, Chidambaram A . Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996; 85(6):841-51. DOI: 10.1016/s0092-8674(00)81268-4. View

5.
Regl G, Neill G, Eichberger T, Kasper M, Ikram M, Koller J . Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma. Oncogene. 2002; 21(36):5529-39. DOI: 10.1038/sj.onc.1205748. View